About: Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.98 (-0.76%)
COCP NASDAQ Cocrystal Pharma Inc
Cocrystal Pharma Inc share price
Atividade de preço de COCP
Último preço
$ 0,980
Variação (24h)
-0,01 USD (0,76%)
Volume
14.73K
Volume (média 4 sem.)
-
Abertura
$ 0,97
Variação do dia
$ 0,97 - $ 0,98
Fechamento anterior
$ 0,99
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
COCP price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals